newsfilter
← Latest News
Business Wire·

Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026

  • Innate Pharma SA will host an in-person & virtual event on November 18, 2026, at 11:00 AM ET / 4:00 PM GMT in London to discuss IPH4502.
  • Professor Yohann Loriot will present Phase 1 clinical data from the IPH4502 dose-escalation study at the 2026 EORTC-NCI-AACR Symposium.
  • The event will cover safety, pharmacokinetics, antitumor activity, the current urothelial cancer treatment landscape, & unmet medical needs.
  • IPH4502 is a proprietary Nectin-4 antibody-drug conjugate featuring exatecan as the payload, a stable linker, & a humanized anti-Nectin-4 antibody.
  • Preclinical studies show IPH4502 has activity in EV-resistant models & tumors with low or heterogeneous Nectin-4 expression.
  • The drug is currently being evaluated in the Phase 1 IPH4502-101 study for patients with advanced solid tumors expressing Nectin-4.
  • IPH4502 has not received marketing authorization in the European Union or FDA approval, & its safety & efficacy remain unestablished for commercial use.
  • Innate Pharma is a global clinical-stage biotechnology company listed on Euronext Paris & Nasdaq, focusing on ADCs & immunotherapies.